Similar Search Results

Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn’s Disease

Yu, Andrew; Johnson, Scott; Wang, Si-Tien; Atanasov, Pavel - In: PharmacoEconomics 27 (2009) 7, pp. 609-621

<Emphasis Type="Bold">Objective: To determine and compare the cost utilities of the tumour necrosis factor (TNF) antagonists adalimumab and infliximab as maintenance therapies for patients in the US with moderately to severely active Crohn’s disease. <Emphasis Type="Bold">Methods: Maintenance regimens of adalimumab (40 mg every other...</emphasis></emphasis>

Persistent link: https://www.econbiz.de/10011001569

Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn's Disease

Yu, Andrew P.; Johnson, Scott; Wang, Si-Tien; Atanasov, … - In: PharmacoEconomics 27 (2009) 7, pp. 609-621

Objective: To determine and compare the cost utilities of the tumour necrosis factor (TNF) antagonists adalimumab and infliximab as maintenance therapies for patients in the US with moderately to severely active Crohn's disease. Methods: Maintenance regimens of adalimumab (40 mg every other...

Persistent link: https://www.econbiz.de/10004982121